Tempest Therapeutics (TPST) Total Liabilities (2011 - 2026)

Tempest Therapeutics has disclosed Total Liabilities across 16 years of filings, most recently posting $10.7 million for Q2 2026.

• In Q2 2026, Total Liabilities fell 27.06% year-over-year to $10.7 million; the TTM figure through Jun 2026 stood at $10.7 million (down 27.06% YoY), while the FY2025 annual figure was $10.3 million, down 54.11% from the prior year.
• Total Liabilities came in at $10.7 million for Q2 2026 at Tempest Therapeutics, up from $10.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $37.6 million in Q1 2022 to a low of $10.3 million in Q4 2025.
• Average Total Liabilities over 5 years is $23.6 million, with a median of $24.8 million recorded in 2023.
• Year-over-year, Total Liabilities jumped 54.19% in 2022 and slumped 54.11% in 2025.
• Over 5 years, Total Liabilities stood at $28.0 million in 2022, then fell by 11.23% to $24.8 million in 2023, then decreased by 9.96% to $22.4 million in 2024, then tumbled by 54.11% to $10.3 million in 2025, then increased by 4.48% to $10.7 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $10.7 million in Q2 2026, $10.3 million in Q4 2025, and $10.8 million in Q3 2025.